Insider Transactions in Q1 2026 at Maze Therapeutics, Inc. (MAZE)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
Harold Bernstein President, R&D & CMO |
SELL
Open market or private sale
|
Direct |
25,156
-100.0%
|
$1,006,240
$40.2 P/Share
|
|
Jan 07
2026
|
Harold Bernstein President, R&D & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,156
+50.0%
|
$251,560
$10.42 P/Share
|
|
Jan 07
2026
|
Catherine A. Sohn |
SELL
Open market or private sale
|
Direct |
26,920
-100.0%
|
$1,049,880
$39.11 P/Share
|
|
Jan 07
2026
|
Catherine A. Sohn |
BUY
Exercise of conversion of derivative security
|
Direct |
26,920
+23.92%
|
$269,200
$10.42 P/Share
|
|
Jan 06
2026
|
Catherine A. Sohn |
SELL
Open market or private sale
|
Direct |
2,493
-100.0%
|
$94,734
$38.62 P/Share
|
|
Jan 06
2026
|
Catherine A. Sohn |
BUY
Exercise of conversion of derivative security
|
Direct |
2,493
+50.0%
|
$24,930
$10.42 P/Share
|
|
Jan 05
2026
|
Harold Bernstein President, R&D & CMO |
SELL
Open market or private sale
|
Direct |
412
-100.0%
|
$16,480
$40.0 P/Share
|
|
Jan 05
2026
|
Harold Bernstein President, R&D & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
412
+50.0%
|
$4,120
$10.42 P/Share
|
|
Jan 02
2026
|
Amy Bachrodt SVP, Finance |
SELL
Open market or private sale
|
Direct |
5,000
-15.03%
|
$195,000
$39.14 P/Share
|
|
Jan 02
2026
|
Amy Bachrodt SVP, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.3%
|
$50,000
$10.42 P/Share
|
|
Jan 02
2026
|
Harold Bernstein President, R&D & CMO |
SELL
Open market or private sale
|
Direct |
4,432
-100.0%
|
$177,280
$40.43 P/Share
|
|
Jan 02
2026
|
Harold Bernstein President, R&D & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,432
+50.0%
|
$44,320
$10.42 P/Share
|